



Key facts on "MenAfriVac™", the meningococcal A conjugate vaccine developed by MVP

- MenAfriVac has successfully gone through phase 1, phase 2, and phase 2/3 clinical trials in India and/or Africa. It is undergoing additional testing in different sites.
- MenAfriVac will help fight group A meningococcus, which is responsible for about 85 percent of meningitis epidemics in Africa.
- MenAfriVac is expected to have a major effect on public health by eliminating group A **epidemic** meningitis in sub-Saharan Africa.
- In addition, MenAfriVac is expected to cut **endemic** meningitis by 50 percent (the proportion of endemic meningitis caused by group A meningococci).
- MenAfriVac is an inactive vaccine that cannot cause meningitis.
- MenAfriVac will ONLY be effective against group A meningococcal meningitis. It will not offer any protection against meningococcal meningitis caused by other groups, and it will not protect against meningitis caused by other bacteria (e.g. Hib, streptococcus).
- No vaccine is 100 percent effective. Some people will not respond to MenAfriVac.
- The cost of MenAfriVac has been negotiated in advance to US\$0.40 per dose. Future price increases will be linked to worldwide inflation.
- MenAfriVac is developed by Serum Institute of India Ltd., the world's largest manufacturer of measles vaccine and diphtheria-tetanus-pertussis vaccines.